<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02849106</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2009-08</org_study_id>
    <nct_id>NCT02849106</nct_id>
  </id_info>
  <brief_title>Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer</brief_title>
  <acronym>CULTURE3D</acronym>
  <official_title>Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer: a Preliminary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, open labelled, multicenter trial to evaluate the feasibility of ex vivo culture&#xD;
      3D (chemogram obtaining) on biopsies in order to estimate the predictive value of this&#xD;
      technique for treatment response in patients treated by two different chemotherapies (FOLFOX&#xD;
      or FOLFIRI) for colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CULTURE 3D study is a prospective, open labelled, multicenter trial. The aim is to&#xD;
      evaluate the feasibility of ex vivo culture 3D (chemogram) on biopsies in order to estimate&#xD;
      the predictive value of this technique for treatment response in patients treated by two&#xD;
      different chemotherapies (FOLFOX or FOLFIRI) for colorectal cancer.&#xD;
&#xD;
      Patients will have biopsies in a metastasis or in the primitive tumor before treatment. The&#xD;
      sample will be used for a 3D ex vivo cells culture. A chemogram will be made based on cells&#xD;
      proliferation data (Ki67) and apoptosis (M30).&#xD;
&#xD;
      Results from this chemogram will not interfere with the treatment combination choice.&#xD;
&#xD;
      The treatment response will be evaluated by the RECIST assessment and will be then compared&#xD;
      to the chemogram.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of interpretable chemogram</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>In ex vivo 3D culture from tumor biopsies, number of interpretable chemogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between chemogram results obtained by 3D culture and RECIST 1.1 response assessement.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Number of chemogram showing the same response to treatment than patient RECIST 1.1 measured response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemosensitivity evaluated on 3D culture.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>on untreated and treated fragments : proliferating index (ki67) and apoptosis (M30) will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to obtain chemogram</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>biopsy to obtain a chemogram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy to obtain a chemogram</intervention_name>
    <description>All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells</description>
    <arm_group_label>biopsy to obtain a chemogram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 years old or more&#xD;
&#xD;
          2. Colorectal cancer with synchronous or metachronous metastases&#xD;
&#xD;
          3. Metastasis and/or primitive tumor (in case of synchronous metastases) accessible to&#xD;
             biopsy&#xD;
&#xD;
          4. Measurable metastatic disease (echography, CT and/or MRI, PET-FDG)&#xD;
&#xD;
          5. Indication for treatment with a combination including FOLFOX/FOLFIRI associated to an&#xD;
             anti VEGF drug (Avastin)&#xD;
&#xD;
          6. No adjuvant chemotherapy for the primitive colorectal cancer and no line of&#xD;
             chemotherapy for metastatic disease during the year prior to inclusion.&#xD;
&#xD;
          7. Life expectancy &gt; 3 months (ECOG 0-1-2).&#xD;
&#xD;
          8. Informed and signed consent by the patient.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Elevation of Carcinoembryonic antigen (CEA) without measurable metastatic disease&#xD;
&#xD;
          2. Medical contraindication to chemotherapy or biotherapy as FOLFOX/FOLFIRI or Avastin.&#xD;
&#xD;
          3. Treatment with FOLFOX/FOLFIRI and biotherapy anti-EGFR (epidermal growth factor&#xD;
             receptor)(Erbitux) planned&#xD;
&#xD;
          4. Patient already enrolled in an other clinical trial with another first line of&#xD;
             chemotherapy.&#xD;
&#xD;
          5. Pregnant women, breastfeeding or of childbearing age not taking contraceptive&#xD;
&#xD;
          6. Persons deprived of liberty.&#xD;
&#xD;
          7. Subject unable to make follow up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascale Mariani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>3D culture</keyword>
  <keyword>chemogram</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

